Boehringer posts BI 1291583 bioavailability results; registers three new trials

Boehringer Ingelheim had one completed study post results and three newly registered trials during the week.

• BI 1291583 (also called Verducatib), a Phase 1 study in healthy male volunteers testing absolute oral bioavailability, is listed as completed with results posted. The trial enrolled 14 participants¹ and compared oral tablet doses against an intravenous microtracer dose; zero of seven participants in either the 1 mg or 5 mg tablet arms had serious adverse events.¹
• BI 4015092, a first-in-human Phase 1 trial, is not yet recruiting. The study is testing the drug as monotherapy and in combination with cetuximab in patients with advanced or metastatic solid tumors, including colorectal cancer and pancreatic ductal adenocarcinoma, who carry a KRAS G12D gene mutation², with an estimated enrollment of 200 participants and a start date of 2026-12-07.
• BI 3810477, a Phase 2a trial in idiopathic pulmonary fibrosis, is not yet recruiting. The randomized, placebo-controlled study aims to find out whether the medicine can slow down the worsening of lung function in people with IPF³, with an estimated enrollment of 70 participants and a primary endpoint of change in forced vital capacity at Week 12.
• The "J-HERZ" observational study of zongertinib in Japan is not yet recruiting, sponsored by Boehringer Ingelheim with the Japan Lung Cancer Society as collaborator. The study will track Japanese patients with HER2-mutated NSCLC across first-, second-, and third-line treatment groups⁴, with an estimated enrollment of 300 participants and a start date of 2026-11-17.